Article Text

Download PDFPDF

A magic bullet for gout?
  1. Alexander So,
  2. Nathalie Busso
  1. Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  1. Correspondence to Professor A So, Department of Rheumatology, University Hospital Lausanne, 1011, Lausanne, Switzerland;{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Do we need new treatments for gout? Hyperuricaemia, the metabolic condition underlying gouty inflammation, has attracted recent attention as new urate-lowering treatments emerge on the horizon. For an acute attack of gout, the currently available drugs—non-steroidal anti-inflammatory drugs, colchicine and corticosteroids, seem to do a pretty good job for the majority of patients in relieving the acute symptoms of inflammation. However, recent data have highlighted the epidemiological shifts in the gouty population towards a more elderly group of patients who often present multiple medical problems. This as well as clinical practice have made us aware that our current treatments of acute gout are not ideal in all situations. They may cause significant side effects in patients with poor renal and cardiac function, and practical experience indicates that quite a number of patients with chronic gout end up receiving long-term steroids, with all the side effects that such treatment engenders. Furthermore, there are abundant reports pointing out that gout is poorly managed in routine clinical practice, suggesting that we are not using all the tools at our disposition adequately. Any new treatment for gout should therefore offer distinct advantages over existing ones to justify its introduction.

With the discovery of the inflammasome as a major regulator of interleukin 1β (IL1β) processing and secretion in macrophages and dendritic cells, IL1 has once again returned to the spotlight as a mediator of acute inflammation. The identification of mutations in the NALP3 gene, a component of the inflammasome, in patients with a subset within the autoinflammatory syndromes (now called cryopyrin-associated periodic syndromes or CAPS) led to the idea of targeting IL1β in this disease. The results have been spectacular1 2 and confirmed that IL1 inhibitors can have major clinical effects if the physiopathology of the disease involves excessive IL1 production. Martinon et al showed that monosodium urate (MSU) crystals can directly trigger the inflammasome to process IL1β, implying that acute gout may also be an IL1β-mediated disease.3 This concept has been strengthened by the findings of an open study on the effects of anakinra in gout4 and the articles by Torres and Terkeltaub in this issue of the journal (see articles on pages 1602 and 1613).5 6 Torres showed convincingly in his animal studies that IL1 is a major trigger of joint inflammation. Using a new animal model of gout, where he injected MSU crystals directly into the mouse ankle joint, he showed that signs and symptoms of acute inflammation were significantly reduced in the mice deficient for the IL1 receptor (IL1R) or when the action of IL1 was blocked by IL1 Trap (also called rilonacept), a molecule that has recently been licensed for the treatment of CAPS (fig 1). The novelty of his model was the measurement of nociception and mobility in mice, readouts that reflect the functional impairment caused by joint inflammation.

Figure 1

Mode of action of interleukin 1 (IL1) and its inhibitors. (A) Binding of IL1β to the IL1 receptor type I (IL1RI) heterodimer complex results in signal transduction. IL1β binds to the membrane-bound IL1RI to form a complex with the IL1 receptor accessory protein (IL1RAcP). This complex recruits the IL1RI-associated kinase (IRAK), leading to signal transduction and gene activation. Receptor activation on cartilage and bone cells promotes cartilage breakdown and bone resorption within the joints. In the bone marrow, IL1β mobilises granulocyte progenitors and mature neutrophils, increases platelet production and augments lymphocyte responses to antigen and mitogens, leading to exacerbation of inflammatory responses. In the brain, IL1β triggers IL1 receptors in the hypothalamus, activating the centre for fever production via production of cyclo-oxygenase-2 and prostaglandin E2. IL1 also activates the endothelium to increase leukocyte adhesion and the production of IL6. (B) Anakinra is an antagonist of IL1 activity. Anakinra is a non-glycosylated recombinant human IL1 receptor antagonist (IL1Ra) that is produced in Escherichia coli. It binds to the IL1RI with similar affinity as IL1 but prevents IL1RAcP binding thus preventing signal transduction. Anakinra mimics the action of the endogenous IL1Ra, and inhibits both the membrane-bound IL1 and circulating IL1 isoforms. (C) Rilonacept inhibits IL1 activity. Rilonacept (also called IL1 Trap) is a recombinant protein comprising the extracellular domains of both IL1RI (red) and adaptor protein IL1RAcP (green) linked by the Fc region of the human IgG1 molecule (represented in brown). Rilonacept binds to IL1α, IL1β and IL1Ra (with a lower affinity), thus preventing IL1 from binding to IL1RI. CRP, C-reactive protein; SAA, serum amyloid A.

The same molecule, rilonacept, was tested in man by Terkeltaub and his colleagues in a small pilot study on 10 patients with chronic gout to validate the concept of IL1 inhibition for acute signs and symptoms of gout (fig 1). In comparison with the run-in period when patients received placebo, patients who received rilonacept weekly over 6 weeks showed a significant reduction in pain score and in C-reactive protein. The reduction in symptoms and signs were significant at 2, 4 and 6 weeks, but there were no data on the response in the first days after starting treatment. Six weeks after the end of treatment, there was a recurrence of joint pain. These two reports make the case for IL1 inhibition in acute gout even stronger, and the results of controlled clinical trials are eagerly awaited to confirm this hypothesis.

These studies raise a number of questions about the role of IL1 in gout. First, does IL1 account for the signs and symptoms seen in acute gout? How does IL1 act? The biology of IL1 in inflammation has been well studied.7 IL1 is a powerful endogenous pyrogen and stimulates endothelial adhesion to facilitate migration of leucocytes to sites of inflammation. The direct effects of IL1 include fever and modulation of nociception by its action on pain thresholds. It also acts indirectly to recruit neutrophils. In an elegant study by Chen and colleagues, the target of action of IL1 released from cells exposed to MSU crystals was shown to be non-bone marrow-derived cells, as bone marrow chimeric mice (wild-type bone marrow transferred to IL1R knockout (KO) mice) did not mount an inflammatory response when challenged with an intraperitoneal injection of MSU crystals. These results showed that non-haemopoietic cells are critical for the expression of inflammation, and the most likely candidate is endothelial cells.8 Figure 2 shows the proposed model to explain how IL1 is critical to inflammation. A secondary question is whether IL1β alone accounts for inflammation, or does IL1α also play a role? As anakinra and rilonacept block both forms of IL1, we do not have a clear answer from these results. A monoclonal antibody specific for IL1β is effective in the treatment of CAPS, and clinical studies are in progress in gout, so we will have a definitive answer in due course.

Figure 2

Multiple steps in the inflammatory cascade initiated by monosodium urate (MSU) crystals. (1) MSU crystals are detected by the pattern recognition molecules of the innate immune system, such as the Toll-like receptors. (2) MSU crystals are phagocytosed by macrophages. (3) Intracellular MSU crystals activate the NALP3 inflammasome, a multi-protein complex composed of the NALP3 sensor, the ASC adaptor protein and the procaspase-1. This induces cleavage of procaspase-1 to its active form, caspase-1. Caspase-1 in turn cleaves inactive pro-IL1β to generate IL1β. (4) Active IL1β is then released into extracellular fluids (synovial fluid, plasma…). (5) IL1β activates IL1 receptors on the endothelium, resulting in signal transduction and gene activation. (6) An array of proinflammatory cytokines and chemokines, including IL8, is secreted by endothelial cells, which increase cell adhesion molecules on the endothelium. (7) Neutrophils are recruited leading to accumulation of these cells within the joint. (8) Amplification of the inflammatory cascade by neutrophil release of more IL1β and other proinflammatory cytokines.

Apart from IL1, are other cytokines involved in acute gouty inflammation? From the results obtained in Torres’ study, multiple proinflammatory cytokines and chemokines are upregulated at the same time as IL1β, including tumour necrosis factor α (TNFα), IL6, granulocyte-colony stimulating factor (G-CSF), KC (CXCL-1) and MCP-1 (CCL2). Interestingly, when the action of IL1 was blocked (in the IL1R KO or by rilonacept), upregulation of TNF, IL6 and G-CSF was also attenuated, but the production of the chemokines were less affected. These findings suggest a hierarchical order of cytokine production when MSU triggers inflammatory processes, some of which are IL1 dependent. To date, there are few clinical data to show that TNFα or IL6 blockade is clinically effective for gout, but it would be of interest to compare the effects of inhibiting different cytokines in vivo. From the available data, it appears that inhibiting IL1 alone in vivo can successfully turn off the inflammatory process, suggesting that IL1β release is indeed at the starting point of acute gout.

If indeed IL1 inhibition turns out to be an effective treatment, the questions that will be asked will include whether such an approach is warranted and what are the associated risks? The experience with IL1 inhibitors in clinical use (with agents such as anakinra and canakinumab) indicates that the treatment is generally safe, though there are always concerns about infectious complications when proinflammatory cytokines are inhibited. However, if inhibition is applied only in an acute setting, such complications should be less prominent than in chronic inhibition, as used when treating rheumatoid arthritis. If this treatment were to be applied to acute gout in the future, it would be vital that the target group of patients is clearly defined to justify its use over that of conventional agents, and that septic arthritis is excluded for obvious safety reasons.

Current research into the biochemical pathways that MSU crystals employ to trigger inflammation will open novel perspectives on anti-inflammatory treatment. Our understanding of the steps leading to the assembly of the inflammasome is still sketchy, but other molecules such as reactive oxygen species and purinergic receptors have been reported to be implicated.9 10 We should also not forget that MSU crystals can activate other inflammatory pathways, such as complement and mast cells. If we can put all this information together in a functional system, perhaps one day we will be able to select the target that is the most appropriate for a given patient to suppress the inflammatory process of acute gout.


View Abstract


  • Competing interests None.

  • Provenance and Peer review Commissioned; externally peer reviewed.

Linked Articles